tetano
Editor, Senior Moderator
J Gen Virol. 2017 Nov 15. doi: 10.1099/jgv.0.000977. [Epub ahead of print]
[h=1]In vivo mallard experiments indicate that zanamivir has less potential for environmental influenza A virus resistance development than oseltamivir.[/h] Nykvist M[SUP]1[/SUP], Gillman A[SUP]2[/SUP], S?derstr?m Lindstr?m H[SUP]3,[/SUP][SUP]4[/SUP], Tang C[SUP]4[/SUP], Fedorova G[SUP]5[/SUP], Lundkvist ?[SUP]1[/SUP], Latorre-Margalef N[SUP]6[/SUP], Wille M[SUP]7,[/SUP][SUP]1[/SUP], J?rhult JD[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Neuraminidase inhibitors are a cornerstone of influenza pandemic preparedness before vaccines can be mass-produced and thus a neuraminidase inhibitor-resistant pandemic is a serious threat to public health. Earlier work has demonstrated the potential for development and persistence of oseltamivir resistance in influenza A viruses exposed to environmentally relevant water concentrations of the drug when infecting mallards, the natural influenza reservoir that serves as the genetic base for human pandemics. As zanamivir is the major second-line neuraminidase inhibitor treatment, this study aimed to assess the potential for development and persistence of zanamivir resistance in an in vivo mallard model; especially important as zanamivir will probably be increasingly used. Our results indicate less potential for development and persistence of resistance due to zanamivir than oseltamivir in an environmental setting. This conclusion is based on: (1) the lower increase in zanamivir IC50 conferred by the mutations caused by zanamivir exposure (2-17-fold); (2) the higher zanamivir water concentration needed to induce resistance (at least 10 ?g l[SUP]-1[/SUP]); (3) the lack of zanamivir resistance persistence without drug pressure; and (4) the multiple resistance-related substitutions seen during zanamivir exposure (V116A, A138V, R152K, T157I and D199G) suggesting lack of one straight-forward evolutionary path to resistance. Our study also adds further evidence regarding the stability of the oseltamivir-induced substitution H275Y without drug pressure, and demonstrates the ability of a H275Y-carrying virus to acquire secondary mutations, further boosting oseltamivir resistance when exposed to zanamivir. Similar studies using influenza A viruses of the N2-phylogenetic group of neuraminidases are recommended.
PMID: 29139346 DOI: 10.1099/jgv.0.000977
[h=1]In vivo mallard experiments indicate that zanamivir has less potential for environmental influenza A virus resistance development than oseltamivir.[/h] Nykvist M[SUP]1[/SUP], Gillman A[SUP]2[/SUP], S?derstr?m Lindstr?m H[SUP]3,[/SUP][SUP]4[/SUP], Tang C[SUP]4[/SUP], Fedorova G[SUP]5[/SUP], Lundkvist ?[SUP]1[/SUP], Latorre-Margalef N[SUP]6[/SUP], Wille M[SUP]7,[/SUP][SUP]1[/SUP], J?rhult JD[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Neuraminidase inhibitors are a cornerstone of influenza pandemic preparedness before vaccines can be mass-produced and thus a neuraminidase inhibitor-resistant pandemic is a serious threat to public health. Earlier work has demonstrated the potential for development and persistence of oseltamivir resistance in influenza A viruses exposed to environmentally relevant water concentrations of the drug when infecting mallards, the natural influenza reservoir that serves as the genetic base for human pandemics. As zanamivir is the major second-line neuraminidase inhibitor treatment, this study aimed to assess the potential for development and persistence of zanamivir resistance in an in vivo mallard model; especially important as zanamivir will probably be increasingly used. Our results indicate less potential for development and persistence of resistance due to zanamivir than oseltamivir in an environmental setting. This conclusion is based on: (1) the lower increase in zanamivir IC50 conferred by the mutations caused by zanamivir exposure (2-17-fold); (2) the higher zanamivir water concentration needed to induce resistance (at least 10 ?g l[SUP]-1[/SUP]); (3) the lack of zanamivir resistance persistence without drug pressure; and (4) the multiple resistance-related substitutions seen during zanamivir exposure (V116A, A138V, R152K, T157I and D199G) suggesting lack of one straight-forward evolutionary path to resistance. Our study also adds further evidence regarding the stability of the oseltamivir-induced substitution H275Y without drug pressure, and demonstrates the ability of a H275Y-carrying virus to acquire secondary mutations, further boosting oseltamivir resistance when exposed to zanamivir. Similar studies using influenza A viruses of the N2-phylogenetic group of neuraminidases are recommended.
PMID: 29139346 DOI: 10.1099/jgv.0.000977